Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: Dexanabinol and PRS-211,220

European Journal of Pharmaceutical Sciences

Volumn 31, Issue 5, 2007, Pages 298-305

  Gershkovich, Pavel ^a   Qadri, Bashir ^a   Yacovan, Avihai ^b   Amselem, Shimon ^b   Hoffman, Amnon ^a  

^a Faculty of Medicine   (Israel)

^b PHARMOS LTD   (Israel)

Author keywords

Bioavailability; Cannabinoids; Chylomicrons; Lipophilicity; Lymphatic transport

Indexed keywords

ARACHIS OIL; CANNABINOID DERIVATIVE; CHYLOMICRON; DEXANABINOL; LONG CHAIN TRIACYLGLYCEROL; PRS 211220; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STRUCTURE; EX VIVO STUDY; INTESTINE ABSORPTION; LIPOPHILICITY; LYMPHATIC SYSTEM; MALE; MEASUREMENT; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CANNABINOIDS; CORN OIL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; IMIDAZOLES; INJECTIONS, INTRAVENOUS; INTESTINES; LYMPHATIC SYSTEM; MALE; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PLANT OILS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROCANNABINOL;

EID: 34447512868     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.04.006     Document Type: Article

References (42)

1. Agurell S., Halldin M., Lindgren J.E., Ohlsson A., Widman M., Gillespie H., and Hollister L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38 (1986) 21-43
2. Bland T.M., Haining R.L., Tracy T.S., and Callery P.S. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem. Pharmacol. 70 (2005) 1096-1103
3. Bollman J.L., Cain J.C., and Grindlay J.H. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J. Lab. Clin. Med. (1948) 33
4. Brocks D.R., Ala S., and Aliabadi H.M. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm. Drug Dispos. 27 (2006) 7-16
5. Caliph S.M., Charman W.N., and Porter C.J. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 89 (2000) 1073-1084
6. Charman W.N. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci. 89 (2000) 967-978
7. Charman W.N., and Porter C.J. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Deliv. Rev. 19 (1996) 149-169
8. Charman W.N., and Stella V.J. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 34 (1986) 175-178
9. Dahan A., and Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 24 (2005) 381-388
10. Dahan A., and Hoffman A. Enhanced gastrointestinal absorption of lipophilic drugs. In: Touitou E., and Barry B.W. (Eds). Enhancement in Drug Delivery (2006), CRC Press 111-127
11. Dahan A., and Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm. Res. 23 (2006) 2165-2174
12. Eder H.A. The effect of diet on the transport of probucol in monkeys. Artery 10 (1982) 105-107
13. Edwards G.A., Porter C.J., Caliph S.M., Khoo S.M., and Charman W.N. Animal models for the study of intestinal lymphatic drug transport. Adv. Drug Deliv. Rev. 50 (2001) 45-60
14. Gershkovich P., and Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. 26 (2005) 394-404
15. Gershkovich P., Shtainer D., and Hoffman A. The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. Int. J. Pharm. 333 (2007) 1-4
16. Grove M., Nielsen J.L., Pedersen G.P., and Mullertz A. Bioavailability of Seocalcitol IV: evaluation of lymphatic transport in conscious rats. Pharm. Res. 23 (2006) 2681-2688
17. Gupta S.K., and Benet L.Z. High-fat meals increase the clearance of cyclosporine. Pharm. Res. 7 (1990) 46-48
18. Hauss D.J., Mehta S.C., and Radebaugh G.W. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int. J. Pharm. 108 (1994) 85-93
19. Holm R., and Hoest J. Successful in silico predicting of intestinal lymphatic transfer. Int. J. Pharm. 272 (2004) 189-193
20. Holm R., Porter C.J., Edwardsm G.A., Mullertz A., Kristensen H.G., and Charman W.N. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur. J. Pharm. Sci. 20 (2003) 91-97
21. Humberstone A.J., Cowman A.F., Horton J., and Charman W.N. Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum. J. Pharm. Sci. 87 (1998) 256-258
22. Humberstone A.J., Porter C.J., Edwards G.A., and Charman W.N. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87 (1998) 936-942
23. Khoo S.M., Edwards G.A., Porter C.J., and Charman W.N. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J. Pharm. Sci. 90 (2001) 1599-1607
24. Khoo S.M., Shackleford D.M., Porter C.J., Edwards G.A., and Charman W.N. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm. Res. 20 (2003) 1460-1465
25. Lavie V., Bar-Joseph A., Berckovitch Y., Azulay M., Weksler A., Grienstein Y., Garzon A., Greenberg O., Elgamiel R., Amselem S., and Fink G. Neuroprotection by PRS-211,220: Assessed Functionally and Morphologically in Transient MCA Occlusion in Rats (2002), Pharmacology of Cerebral Ischemia, Marburg, Germany
26. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
27. Maas A.I., Murray G., Henney H., Kassem N., Legrand V., Mangelus M., Muizelaar J.P., Stocchetti N., and Knoller N. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 5 (2006) 38-45
28. Mattes R.D., Shaw L.M., Edling-Owens J., Engelman K., and Elsohly M.A. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol. Biochem. Behav. 44 (1993) 745-747
29. McIntosh M.P., Batey A.J., Coker S.J., Porter C.J., and Charman W.N. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model. J. Pharm. Pharmacol. 56 (2004) 69-77
30. Myers R.A., and Stella V.J. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int. J. Pharm. 80 (1992) 51-62
31. O'Driscoll C.M. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15 (2002) 405-415
32. Porter C.J., Charman S.A., and Charman W.N. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J. Pharm. Sci. 85 (1996) 351-356
33. Porter C.J., and Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50 (2001) 61-80
34. Shayeganpour A., Jun A.S., and Brocks D.R. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm. Drug Dispos. 26 (2005) 249-257
35. Shohami E., Novikov M., and Bass R. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res. 674 (1995) 55-62
36. Trevaskis N.L., Porter C.J., and Charman W.N. Bile increases intestinal lymphatic drug transport in the fasted rat. Pharm. Res. 22 (2005) 1863-1870
37. Trevaskis N.L., Porter C.J., and Charman W.N. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab. Dispos. 34 (2006) 729-733
38. Trevaskis N.L., Porter C.J., and Charman W.N. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J. Pharmacol. Exp. Ther. 316 (2006) 881-891
39. Warshaw A.L. A simplified method of cannulating the intestinal lymphatic of the rat. Gut 13 (1972) 66-67
40. Wasan K.M., and Cassidy S.M. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87 (1998) 411-424
41. Wasan K.M., Ramaswamy M., Kwong M., and Boulanger K.D. Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A. AAPS Pharm. Sci. 4 (2002) E30
42. Wasan K.M., Wong J.C., Corr T., and Pritchard S. Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. Cancer Chemother. Pharmacol. 57 (2006) 120-124